Subscribe to RSS
DOI: 10.1160/TH08-01-0015
Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis
Publication History
Received:
09 January 2008
Accepted after major revision:
19 September 2008
Publication Date:
23 November 2017 (online)
Summary
Transcatheter local thrombolytic therapy in patients with acute, extended splanchnic venous thrombosis is controversial. Here we present our single-center experience with transcatheter thrombolytic therapy in these patients. All consecutive patients (n=12) with acute,extended splanchnic venous thrombosis who underwent transcatheter thrombolytic therapy in our hospital, were included in this study. Thrombolytic therapy was successful for three thrombotic events and partially successful for four thrombotic events.Two patients developed minor procedure-related bleeding (17%).Six patients (50%) developed major procedure-related bleeding, with a fatal outcome in two. Transcatheter thrombolytic therapy in patients with acute, extended splanchnic vein thrombosis is found to be associated with a high rate of procedure-related bleeding. Therefore, thrombolysis should be reserved for patients in whom the venous flow cannot be restored by using conventional anticoagulant therapy or stent placement across the thrombosed vessel segment.
H.L.A. Janssen and F.W.G. Leebeek are both Clinical Fellows of the Netherlands Organisation for Scientific Research (NWO).
Keywords
Thrombosis (venous) - portal vein thrombosis - Budd-Chiari syndrome - thrombolytic therapy - rtPA# Current address: Atrium Medical Center, Heerlen, The Netherlands.